Weight-loss prescriptions for Wegovy or off-label use usually require a Letter of Medical Necessity stating that the treatment is medically necessary and not for cosmetic or general wellness purposes

Figure 4: Time to First Occurrence of Hospitalization for Heart Failure or CV Death in the DECLARE Trial Figure 5: Time to First Occurrence of Hospitalization for Heart Failure in the DECLARE Trial 14.4 Chronic Kidney Disease in Adults The Trial to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease (DAPA-CKD, NCT03036150) was an international, multicenter, randomized, double-blind, placebo-controlled trial in adult patients with chronic kidney disease (CKD) (eGFR between 25 and 75 mL/min/1.73 m2) and albuminuria [urine albumin creatinine ratio (UACR) between 200 and 5000 mg/g] who were receiving standard of care background therapy, including a maximally tolerated, labeled daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB)
Both support reproductive timing by synchronizing and stabilizing cycles and reducing stress-related anovulation
Let's use a 200-pound person as an example: A 15% weight loss, a typical result for semaglutide , means shedding 30 pounds
It affects 9 million Americans, yet fewer than one in three patients is getting the treatment they need